Vir Biotechnology Files 8-K on Security Holder Votes

Ticker: VIR · Form: 8-K · Filed: 2025-05-29T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-vote, sec-filing

TL;DR

Vir Bio filed an 8-K for a shareholder vote. No fireworks, just governance.

AI Summary

Vir Biotechnology, Inc. filed an 8-K on May 29, 2025, to report on matters submitted to a vote of its security holders. The filing does not disclose specific details of the vote or any associated resolutions, but it confirms the company's adherence to reporting requirements.

Why It Matters

This filing indicates that Vir Biotechnology held a shareholder vote, a standard corporate governance event. The lack of specific details in this 8-K suggests no immediate material changes or significant shareholder actions were disclosed.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for a shareholder vote without disclosure of specific outcomes or material events, indicating low immediate risk.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Vir Biotechnology's security holders on May 29, 2025?

The 8-K filing does not specify the exact matters submitted for a vote, only that such a submission occurred.

Did the filing disclose the results of the shareholder vote?

No, the filing does not disclose the results of the shareholder vote.

What is the primary purpose of this 8-K filing for Vir Biotechnology?

The primary purpose is to report on the submission of matters to a vote of security holders, as required by SEC regulations.

What is Vir Biotechnology's principal executive office address?

Vir Biotechnology's principal executive offices are located at 1800 Owens Street, Suite 900, San Francisco, California 94158.

What is Vir Biotechnology's IRS Employer Identification Number (EIN)?

Vir Biotechnology's IRS Employer Identification Number is 81-2730369.

From the Filing

0001628280-25-028356.txt : 20250529 0001628280-25-028356.hdr.sgml : 20250529 20250529162110 ACCESSION NUMBER: 0001628280-25-028356 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250529 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250529 DATE AS OF CHANGE: 20250529 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 251003702 BUSINESS ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 8-K 1 vir-20250529.htm 8-K vir-20250529 FALSE 0001706431 0001706431 2025-05-29 2025-05-29 0001706431 exch:XNAS 2025-05-29 2025-05-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 8-K ________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 ________________________________________ Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) ________________________________________ Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1800 Owens Street , Suite 900 San Francisco , California 94158 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: ( 415 ) 906-4324 (Former Name or Former Address, if Changed Since Last Report) ________________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.0001 par value VIR Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 5.07 Submission of Matters to a Vote of Security Holders. On May 29, 2025, Vir Biotechnology, Inc. (the Company) held its 2025 Annual Meeting of Stockholders (the Annual Meeting). As of the close of business on April 1, 2025, the record date for the Annual Meeting, 138,063,698 shares of Company common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. Proposal 1. Election of Directors The Company’s stockholders elected the two persons listed below as Class III directors, each to serve until the Company’s 2028 Annual Meeting of Stockholders and un

View on Read The Filing